Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,291 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Adverse events in the placebo arm of SOLO2/ENGOT-Ov21 maintenance trial of olaparib in recurrent ovarian cancer.
Francis KE, Simon S, Gebski V, Joly F, Ledermann JA, Penson RT, Oza AM, Korach J, Lainez N, Cecere SC, Tasca G, Gropp-Meier M, Fujiwara K, Lowe ES, Friedlander M, Pujade-Lauraine E, Lee CK. Francis KE, et al. Among authors: lee ck. Gynecol Oncol. 2024 Nov 12;192:50-55. doi: 10.1016/j.ygyno.2024.11.004. Online ahead of print. Gynecol Oncol. 2024. PMID: 39536691 Free article.
Efficacy and safety of olaparib according to age in BRCA1/2-mutated patients with recurrent platinum-sensitive ovarian cancer: Analysis of the phase III SOLO2/ENGOT-Ov21 study.
Trillsch F, Mahner S, Ataseven B, Asher R, Aryal N, Dubot C, Clamp A, Penson RT, Oza A, Amit A, Huzarski T, Casado A, Scambia G, Friedlander M, Colombo N, Fujiwara K, Sonke GS, Denys H, Lowe ES, Lee CK, Pujade-Lauraine E. Trillsch F, et al. Among authors: lee ck. Gynecol Oncol. 2022 Apr;165(1):40-48. doi: 10.1016/j.ygyno.2022.01.024. Epub 2022 Jan 31. Gynecol Oncol. 2022. PMID: 35115180 Clinical Trial.
The impact of olaparib dose reduction and treatment interruption on treatment outcome in the SOLO2/ENGOT-ov21 platinum-sensitive recurrent ovarian cancer.
Francis KE, Kim SI, Friedlander M, Gebski V, Ray-Coquard I, Clamp A, Penson RT, Oza A, Perri T, Huzarski T, Martin-Lorente C, Cecere SC, Colombo N, Ataseven B, Fujiwara K, Sonke G, Vergote I, Pujade-Lauraine E, Kim JW, Lee CK. Francis KE, et al. Among authors: lee ck. Ann Oncol. 2022 Jun;33(6):593-601. doi: 10.1016/j.annonc.2022.02.222. Epub 2022 Feb 24. Ann Oncol. 2022. PMID: 35219776 Free article. Clinical Trial.
Impact of secondary cytoreductive surgery on survival in patients with platinum sensitive recurrent ovarian cancer: analysis of the CALYPSO trial.
Lee CK, Lord S, Grunewald T, Gebski V, Hardy-Bessard AC, Sehouli J, Woie K, Heywood M, Schauer C, Vergote I, Scambia G, Ferrero A, Harter P, Pujade-Lauraine E, Friedlander M. Lee CK, et al. Gynecol Oncol. 2015 Jan;136(1):18-24. doi: 10.1016/j.ygyno.2014.09.017. Epub 2014 Oct 2. Gynecol Oncol. 2015. PMID: 25281492 Clinical Trial.
Safety and efficacy of single-agent bevacizumab-containing therapy in elderly patients with platinum-resistant recurrent ovarian cancer: Subgroup analysis of the randomised phase III AURELIA trial.
Sorio R, Roemer-Becuwe C, Hilpert F, Gibbs E, García Y, Kaern J, Huizing M, Witteveen P, Zagouri F, Coeffic D, Lück HJ, González-Martín A, Kristensen G, Levaché CB, Lee CK, Gebski V, Pujade-Lauraine E; AURELIA Investigators. Sorio R, et al. Among authors: lee ck. Gynecol Oncol. 2017 Jan;144(1):65-71. doi: 10.1016/j.ygyno.2016.11.006. Epub 2016 Nov 18. Gynecol Oncol. 2017. PMID: 27871723 Clinical Trial.
Concordance between CA-125 and RECIST progression in patients with germline BRCA-mutated platinum-sensitive relapsed ovarian cancer treated in the SOLO2 trial with olaparib as maintenance therapy after response to chemotherapy.
Tjokrowidjaja A, Lee CK, Friedlander M, Gebski V, Gladieff L, Ledermann J, Penson R, Oza A, Korach J, Huzarski T, Manso L, Pisano C, Asher R, Lord SJ, Kim SI, Lee JY, Colombo N, Park-Simon TW, Fujiwara K, Sonke G, Vergote I, Kim JW, Pujade-Lauraine E. Tjokrowidjaja A, et al. Among authors: lee ck, lee jy. Eur J Cancer. 2020 Nov;139:59-67. doi: 10.1016/j.ejca.2020.08.021. Epub 2020 Sep 23. Eur J Cancer. 2020. PMID: 32977221 Clinical Trial.
Molecular and clinical predictors of improvement in progression-free survival with maintenance PARP inhibitor therapy in women with platinum-sensitive, recurrent ovarian cancer: A meta-analysis.
Lee CK, Friedlander ML, Tjokrowidjaja A, Ledermann JA, Coleman RL, Mirza MR, Matulonis UA, Pujade-Lauraine E, Bloomfield R, Goble S, Wang P, Glasspool RM, Scott CL; Gynecologic Cancer Intergroup Meta-Analysis Committee. Lee CK, et al. Cancer. 2021 Jul 15;127(14):2432-2441. doi: 10.1002/cncr.33517. Epub 2021 Mar 19. Cancer. 2021. PMID: 33740262 Free article.
Reporting the trajectories of adverse events over the entire treatment course in patients with recurrent platinum-sensitive ovarian cancer treated with platinum-based combination chemotherapy regimens: A graphical approach to trial adverse event reporting.
Francis KE, Gebski V, Lord SJ, Friedlander M, Pujade-Lauraine E, Lee CK. Francis KE, et al. Among authors: lee ck. Eur J Cancer. 2021 May;148:251-259. doi: 10.1016/j.ejca.2021.02.006. Epub 2021 Mar 20. Eur J Cancer. 2021. PMID: 33756421 Clinical Trial.
Prognostic nomogram for progression-free survival in patients with BRCA mutations and platinum-sensitive recurrent ovarian cancer on maintenance olaparib therapy following response to chemotherapy.
Tjokrowidjaja A, Friedlander M, Lord SJ, Asher R, Rodrigues M, Ledermann JA, Matulonis UA, Oza AM, Bruchim I, Huzarski T, Gourley C, Harter P, Vergote I, Scott CL, Meier W, Shapira-Frommer R, Milenkova T, Pujade-Lauraine E, Gebski V, Lee CK. Tjokrowidjaja A, et al. Among authors: lee ck. Eur J Cancer. 2021 Sep;154:190-200. doi: 10.1016/j.ejca.2021.06.024. Epub 2021 Jul 19. Eur J Cancer. 2021. PMID: 34293664
3,291 results